Fax: (713) 794-3249
Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies†
Article first published online: 6 JUN 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 24, pages 6144–6151, 15 December 2012
How to Cite
Kurzrock, R., Goel, S., Wheler, J., Hong, D., Fu, S., Rezai, K., Morgan-Linnell, S. K., Urien, S., Mani, S., Chaudhary, I., Ghalib, M. H., Buchbinder, A., Lokiec, F. and Mulcahy, M. (2012), Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer, 118: 6144–6151. doi: 10.1002/cncr.27647
Presented in part at the 44th Annual Meeting of the American Society of Clinical Oncology, May 30 to June 3, 2008, Chicago, IL; and at the American Association for Cancer Research—National Cancer Institute—European Organization for the Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics; November 18, 2009; Boston, MA.
- Issue published online: 3 DEC 2012
- Article first published online: 6 JUN 2012
- Manuscript Accepted: 6 MAR 2012
- Manuscript Received: 2 FEB 2012
- phase 1;
- topoisomerase I;
EZN-2208 is a water-soluble, polyethylene glycol drug conjugate of SN38, which is the active moiety of irinotecan. In this study, the authors evaluated the tolerability, pharmacokinetics (PK), and activity of EZN-2208 in adult patients with advanced solid tumors.
Patients in sequential cohorts (3 + 3 design) received intravenous EZN-2208 at doses between 1.25 mg/m2 and 25 mg/m2 once every 21 days.
Thirty-nine patients received EZN-2208. The median number of prior therapies was 2 (range, 0-10 prior therapies). Seventeen patients received prior irinotecan. Two maximum tolerated doses (MTDs) were defined: EZN-2208 with (16.5 mg/m2) and without (10 mg/m2) granulocyte-colony–stimulating factor (G-CSF). The dose-limiting toxicity (DLT) was febrile neutropenia. Two of 19 patients who were heterozygous for a polymorphism in the uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1) gene (UGT1A1*28) developed DLTs (dose, 25 mg/m2 with G-CSF), and 2 patients who were homozygous for UGT1A1*28 were treated without DLTs (dose, 5 mg/m2). PK analysis indicated a mean terminal half-life of 19.4 ± 3.4 hours. Sixteen patients (41%) achieved stable disease, including 6 of 39 patients (15%) who had stable disease that lasted ≥4 months. One patient with cholangiocarcinoma (no prior irinotecan) achieved a short-lived 32% tumor regression. Among 6 patients who had stable disease that lasted for ≥4 months, 3 had received prior irinotecan, and 1 had KRAS-positive colorectal cancer.
EZN-2208 was well tolerated and produced stable disease that lasted for ≥4 months/unconfirmed partial responses in 7 of 39 heavily pretreated patients (18%) with advanced solid tumors, including those who had failed prior irinotecan therapy. Cancer 2012. © 2012 American Cancer Society.